These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1176 related items for PubMed ID: 19884550

  • 1. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C.
    J Clin Oncol; 2009 Dec 01; 27(34):5751-6. PubMed ID: 19884550
    [Abstract] [Full Text] [Related]

  • 2. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.
    J Clin Oncol; 2005 Sep 01; 23(25):5960-72. PubMed ID: 16087945
    [Abstract] [Full Text] [Related]

  • 3. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 01; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 4. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 01; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 5. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb 01; 11(2):197-205. PubMed ID: 16476840
    [Abstract] [Full Text] [Related]

  • 6. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Feb 01; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 7. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb 01; 11(2):206-16. PubMed ID: 16476841
    [Abstract] [Full Text] [Related]

  • 8. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J, Couture F, Young S, McWatters KL, Lau CY.
    J Clin Oncol; 2005 Apr 20; 23(12):2597-605. PubMed ID: 15452188
    [Abstract] [Full Text] [Related]

  • 9. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.
    J Clin Oncol; 2008 Feb 01; 26(4):592-8. PubMed ID: 18235117
    [Abstract] [Full Text] [Related]

  • 10. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct 01; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 11. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M, Epoetin Alfa Study Group.
    Hematol Oncol; 2003 Dec 01; 21(4):169-80. PubMed ID: 14735555
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ.
    J Clin Oncol; 2005 Dec 20; 23(36):9377-86. PubMed ID: 16361638
    [Abstract] [Full Text] [Related]

  • 13. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
    Rades D, Tribius S, Yekebas EF, Bahrehmand R, Wildfang I, Kilic E, Muellerleile U, Gross E, Schild SE, Alberti W.
    Int J Radiat Oncol Biol Phys; 2006 Jun 01; 65(2):459-65. PubMed ID: 16584851
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar 01; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 15. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
    Agnihotri P, Telfer M, Butt Z, Jella A, Cella D, Kozma CM, Ahuja M, Riaz S, Akamah J.
    J Am Geriatr Soc; 2007 Oct 01; 55(10):1557-65. PubMed ID: 17697104
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.
    Mystakidou K, Kalaidopoulou O, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, Vlahos L.
    Anticancer Res; 2005 Oct 01; 25(5):3495-500. PubMed ID: 16101168
    [Abstract] [Full Text] [Related]

  • 17. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul 01; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN.
    J Clin Oncol; 2007 Mar 20; 25(9):1027-32. PubMed ID: 17312332
    [Abstract] [Full Text] [Related]

  • 19. Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicenter German trial.
    Reinhardt U, Tulusan A, Angermund R, Lutz H, German Epoetin Alfa Study Group.
    Oncologist; 2005 Mar 20; 10(3):225-37. PubMed ID: 15793226
    [Abstract] [Full Text] [Related]

  • 20. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).
    Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, Cmelak AJ, Schulsinger A, Fu KK, Radiation Therapy Oncology Group.
    Int J Radiat Oncol Biol Phys; 2007 Nov 15; 69(4):1008-17. PubMed ID: 17716826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.